Login to Your Account



STRONG RESULTS IN GENOTYPE 1

Enanta, Abbvie impress: 96 percent SVR12 in Phase III hepatitis C trial

By Catherine Shaffer
Staff Writer

Tuesday, December 10, 2013
Enanta Pharmaceuticals Inc. reported an impressive 96 percent sustained virologic response after 12 weeks of treatment (SVR12) for hepatitis C virus (HCV) in its Phase III (SAPPHIREII) study of a regimen containing protease inhibitor ABT-450 (ritonavir).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription